Restenotic Stented Versus De Novo Chronic Total Occlusion Outcomes Following Successful Intervention with Drug-Eluting Stents

Conclusion In our study, there was no difference in 6-to-9 month angiographic and 2-year clinical outcomes between pts with stented and de novo CTO lesions once the CTO pts were successfully treated with DESs.Table 6-to-9 month angiographic and 2-year clinical outcomes Variables, n (%) De Novo CTO (n=249) stented CTO (n=20) P[low *] value 6 to-9 month Angiographic outcomes n=146 n=7 2-yearclinical outcomes n=209 n=17 In-stent restenosis 44 (30.1) 2 (28.6) 0.647 Binary restenosis 22 (15.1) 2 (28.6) 0.302 All death 8 (3.8) 1 (5.9) 0.512 Any myocardial infarction 6 (2.9) 0 (0.0) 0.622 Any Revascularization 37 (17.7) 2 (11.8) 0.410 TLR 28 (13.4) 1 (5.9) 0.328 TVR 32 (15.3) 2 (11.8) 0.513 Non-TVR 5 (2.4) 0 (0.0) 0.674 Total MACE 44 (21.1) 3 (17.6) 0.513 TLR MACE 32 (15.3) 1 (5.9) 0.256 TVR MACE 40 (19.1) 3 (17.6) 0.589 Stent thrombosis 0 (0.0) 1 (0.4) 0.922[low *] Fisher exact test.